Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $116.00 short put and a strike $111.00 long put offers a potential 13.38% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $116.00 by expiration. The full premium credit of $0.59 would be kept by the premium seller. The risk of $4.41 would be incurred if the stock dropped below the $111.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 48.83 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
3 Large-Cap Stocks for June
Thu, 08 Jun 2017 13:44:00 +0000
Not only are these already very big companies, but two are at their all-time highs. We still think they're worth buying now. Keep reading to learn why that's the case.
Why bluebird bio Inc. Flew Higher Again Today
Wed, 07 Jun 2017 20:53:00 +0000
The biotech's post-ASCO run continues.
ASCO Was A Bust For Biotech
Wed, 07 Jun 2017 16:56:00 +0000
The American Society of Clinical Oncology meeting is one of the most closely watched medical conferences of the year. The Wall Street Journal’s “Heard on the Street” columnist Charley Grant noted today that this year’s conference, which ended Tuesday, passed “without much of a stir, at least from an investor point of view.” In short, while some individual stocks rose and fell sharply, the broader S&P Biotechnology Select Industry Index essentially hasn’t moved through Tuesday.
Celgene and Agios Announce Data on Idhifa for Leukemia
Wed, 07 Jun 2017 14:07:02 +0000
Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).
3 Promising Stocks to Buy Now
Wed, 07 Jun 2017 12:22:00 +0000
Shopify, Lumentum, and bluebird bio could be on the cusp of becoming much bigger companies, according to this Motley Fool contributor.
Related Posts
Also on Market Tamer…
Follow Us on Facebook